Ursodeoxycholic acid (Ursosan® capsules)
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE I. V. F. a. s.
Published in:
Gastroent Hepatol 2015; 69(6): 588
Category:
Drug Profile
doi:
https://doi.org/10.14735/amgh2015588
Sources
1. Makino I, Tanaka H. From choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol 1998; 13(6): 659– 664.
2. Roma MG, Toledo FD, Boaglio AC. Ursodeoxycholic acid in cholestasis: linking action mechanic to therapeutic application. Clin Sci (Lond) 2011; 121(12): 523– 544. doi: 10.1042/ CS20110184.
3. Souhrn údajů o přípravku. URSOSAN, 250 mg, tvrdé tobolky, Sp. zn. sukls21251/ /2014. 1– 6.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2015 Issue 6
Most read in this issue
- Ursodeoxycholic acid (Ursosan® capsules)
- Exclusive enteral nutrition – first-line therapy of Crohn’s disease in children
- The results of liver transplantation in Slovak children
- Progressive familial intrahepatic cholestasis type 2 – paediatric patients followed at the Paediatric Clinic of the 2nd Medical Faculty, University Hospital Motol, Prague